Abstract
Studies of myocardial blood flow and substrate metabolism of the human heart with positron emission tomography (PET) have proved clinically useful in patients with coronary artery disease (CAD). The studies allow a comprehensive characterization of the extent and severity of CAD, detection of preclinical coronary disease, and, most importantly, identification of myocardial viability. More broadly, PET provides important novel insights into the physiology and biology of the normal and the diseased heart and explores beneficial effects of new therapeutic interventions and pharmaceuticals. The continued growth of an already large body of scientific literature on cardiac PET is fully acknowledged. However, a complete and well-deserved account of all these accomplishments is beyond the scope of this chapter. If some of these accomplishments are not included, this by no means implies judgment about their quality or relevance but is dictated by the need for brevity. Accordingly, the following chapter focuses on technical aspects of PET that are important for and are unique to the study of the human heart, it reviews observations made with PET in the normal heart and in cardiac disease, and it closes with a discussion of current clinical indications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hoffman EJ, Phelps ME, Wisenberg G, Schelbert HR, Kuhl DE. Electrocardiographic gating in positron emission computed tomography. J Comp Assist Tomogr. 1979; 3: 733–739.
Yamashita K, Tamaki N, Yonekura Y, et al. Quantitative analysis of regional wall motion by gated myocardial positron emission tomography: Validation and comparison with left ventriculography. J Nucl Med. 1989; 30: 1775–1786.
Yamashita K, Tamaki N, Yonekura Y, et al. Regional wall thickening of left ventricle evaluated by gated positron emission tomography in relation to myocardial perfusion and glucose metabolism. J Nucl Med. 1991; 32: 679–685.
Porenta G, Kuhle W, Sinha S, et al. Parameter estimation of cardiac geometry by ECG-gated PET imaging: validation using magnetic resonance imaging and echocardiography. J Nucl Med. 1995; 36: 1123–1129.
Boyd HL, Gunn RN, Marinho NV, et al. Non-invasive measurement of left ventricular volumes and function by gated positron emission tomography. Eur J Nucl Med. 1996; 23: 1594–1602.
Boyd HL, Rosen SD, Rimoldi O, Cunningham VJ, Camici PG. Normal values for left ventricular volumes obtained using gated PET. Gior Ital Cardiol. 1998; 28: 1207–1214.
Hattori N, Bengel FM, Mehilli J, et al. Global and regional functional measurements with gated FDG PET in comparison with left ventriculography. Eur J Nucl Med. 2001; 28: 221–229.
Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comp Assist Tomogr. 1979; 3: 299–308.
Henze E, Huang SC, Ratib O, Hoffman E, Phelps ME, Schelbert HR. Measurements of regional tissue and blood-pool radiotracer concentrations from serial tomographic images of the heart. J Nucl Med. 1983; 24: 987–996.
Sinha S, Sinha U, Czernin J, Porenta G, Schelbert HR. Noninvasive assessment of myocardial perfusion and metabolism: feasibility of registering gated MR and PET images. Am J Roentgen. 1995; 164: 301–307.
Grover-McKay M, Schwaiger M, Krivokapich J, Perloff JK, Phelps ME, Schelbert HR. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy [see comments]. JAm Coll Cardiol. 1989; 13: 317–324.
Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophie cardiomyopathy. Circulation. 1993; 87: 1580–1590.
Parodi O, Schelbert HR, Schwaiger M, Hansen H, Selin C, Hoffman EJ. Cardiac emission computed tomography: underestimation of regional tracer concentrations due to wall motion abnormalities. J Comp Assist Tomogr. 1984; 8: 1083–1092.
Kuhle WG, Porenta G, Huang SC, et al. Quantification of regional myocardial blood flow using 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation. 1992; 86: 1004–1107.
Porenta G, Kuhle W, Czernin J, et al. Semiquantitative assessment of myocardial blood flow and viability using polar map displays of cardiac PET images. J Nucl Med. 1992; 33: 1628–1636.
Nekolla SG, Miethaner C, Nguyen N, Ziegler SI, Schwaiger M. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med. 1998; 25: 1313–1321.
Choi Y, Hawkins RA, Huang SC, et al. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies. J Nucl Med. 1991; 32: 733–738.
Blanksma PK, Willemsen AT, Meeder JG, et al. Quantitative myocardial mapping of perfusion and metabolism using parametric polar map displays in cardiac PET. J Nuel Med. 1995; 36: 153–158.
Hicks K, Ganti G, Mullani N, Gould KL. Automated quantitation of three-dimensional cardiac positron emission tomography for routine clinical use. J Nucl Med. 1989; 30: 1787–1797.
Laubenbacher C, Rothley J, Sitomer J, et al. An automated analysis program for the evaluation of cardiac PET studies: Initial results in the detection and localization of coronary artery disease using nitrogen-13-ammonia. J Nucl Med. 1993; 34: 968–978.
Gould KL. Myocardial perfusion after cholesterol lowering. J Atheroscler Thromb. 1996; 3: 59–61.
Wu HM, Hoh CK, Buxton DB, et al. Quantification of myocardial blood flow using dynamic nitrogen-13-ammonia PET studies and factor analysis of dynamic structures. J Nucl Med. 1995; 36: 2087–2093.
Wu HM, Hoh CK, Choi Y, et al. Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nucl Med. 1995; 36: 1714–1722.
Hermansen F, Ashburner J, Spinks TJ, Kooner JS, Camici PG, Lammertsma AA. Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. J Nuel Med. 1998; 39: 1696–1702.
Renkin EM. Transport of potassium-42 from blood tissue in isolated mammalian skeletal muscles. Am J Physiol. 1959; 197: 1205–1210.
Crone C. Permeability of capillaries in various organs as determined by use of the indicator diffusion method. Acta Physiol Scand. 1963; 58: 292–305.
Schön HR, Schelbert HR, Robinson G, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of C-11 palmitic acid in normal myocardium. Am Heart J. 1982; 103: 532–547.
Schelbert HR, Henze E, Schon HR, et al. C-11 palmitate for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. III. In vivo demonstration of the effects of substrate availability on myocardial metabolism. Am Heart J. 1983; 105: 492–504.
Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest. 1987; 79: 359–366.
Bergmann SR, Fox KA, Rand AL, et al. Quantification of regional myocardial blood flow in vivo with H215O. Circulation. 1984; 70: 724–733.
Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. JAm Coll Cardiol. 1989; 14: 639–652.
Iida H, Takahashi A, Tamura Y, Ono Y, Lammertsma AA. Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation. J Nucl Med. 1995; 36: 78–85.
Hermansen F, Rosen SD, Fath-Ordoubadi F, et al. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med. 1998; 25: 751–759.
Araujo L, Lammertsma A, Rhodes C, et al. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation. 1991; 83: 875–885.
Iida H, Rhodes C, de Silva R, et al. Myocardial tissue fraction-correction for partial volume effects and measure of tissue viability. JNod Med. 1991; 32: 2169–2175.
Iida H, Tamura Y, Kitamura K, Bloomfield PM, Eberl S, Ono Y. Histochemical correlates of (15)O-water-perfusable tissue fraction in experimental canine studies of old myocardial infarction. J Nucl Med. 2000; 41: 1737–1745.
de Silva R, Yamamoto Y, Rhodes CG, et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation. 1992; 86: 1738–1742.
Yamamoto Y, De Silva R, Rhodes C, et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 150-water and dynamic positron emission tomography. Circulation. 1992; 86: 167–178.
Phelps ME, Hoffman EJ, Raybaud C. Factors which affect cerebral uptake and retention of 13NH3. Stroke. 1977; 8: 694–702.
Post RL, Jolly PC. The linkage of sodium, potassium and ammonium active transport across the human erythrocyte membrane. Biochim Biophys Acta. 1957; 25: 118–128.
Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981; 63: 1259–1272.
Bergmann SR, Hack S, Tewson T, Welch MJ, Sobel BE. The dependence of accumulation of 13NH3 by myocardium on metabolic factors and its implications for quantitative assessment of perfusion. Circulation. 1980; 61: 34–43.
Krivokapich J, Keen RE, Phelps ME, Shine KI, Barrio JR. Effects of anoxia on kinetics of [13N] glutamate and 13NH3 metabolism in rabbit myocardium. Circulat Res. 1987; 60: 505–516.
Krivokapich J, Smith GT, Huang SC, et al. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography [see comments]. Circulation. 1989; 80: 1328–1337.
Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol. 1990; 15: 1032–1042.
Bellina CR, Parodi O, Camici P, et al. Simultaneous in vitro and in vivo validation of nitrogen-13-ammonia for the assessment of regional myocardial blood flow. J Nucl Med. 1990; 31: 1335–1343.
Bol A, Melin JA, Vanoverschelde JL, et al. Direct comparison of [13N]ammonia and [150]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation. 1993; 87: 512–525.
Muzik O, Beanlands RS, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med. 1993; 34: 83–91.
Choi Y, Huang SC, Hawkins RA, et al. Quantification of myocardial blood flow using 13N-ammonia and PET: comparison of tracer models. J Nucl Med. 1999; 40: 1045–1055.
Czernin J, Müller P, Chan S, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation. 1993; 88: 62–69.
Wilson R, Laughlin D, Ackell P. Transluminal subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man. Circulation. 1985; 72: 82–89.
Kotzerke J, Glatting G, van den Hoff J, et al. Validation of myocardial blood flow estimation with nitrogen-13 ammonia PET by the argon inert gas technique in humans. Eur J Nucl Med. 2001; 28: 340–345.
Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert HR. Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [150] water techniques. Circulation. 1996; 93: 2000–2006.
Huang SC, Williams BA, Krivokapich J, Araujo L, Phelps ME, Schelbert HR. Rabbit myocardial 82Rb kinetics and a compartmental model for blood flow estimation. Am J Physiol. 1989; 256: H1156 - H1164.
Goldstein RA, Mullani NA, Marani SK, Fisher DJ, Gould KL, O’Brien HA Jr. Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmacologic interventions. J Nucl Med. 1983; 24: 907–915.
Mullani NA, Goldstein RA, Gould KL, et al. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J Nucl Med. 1983; 24: 898–906.
Mullani NA. Myocardial perfusion with rubidium-82: III. Theory relating severity of coronary stenosis to perfusion deficit. J Nucl Med. 1984; 25: 1190–1196.
Budinger TF, Yano Y, Moyer B, Twitchell J, Huesman RH. Myocardial extraction of Rb-82 vs. flow determined by positron emission tomography. J Nucl Med. 1983; 68: III - 81.
Glatting G, Bergmann K, Stollfub J, et al. Myocardial Rb extraction fraction: Determination in humans. J Am Coll Cardiol. 1995; 25: 364A.
Goldstein RA. Kinetics of rubidium-82 after coronary occlusion and reperfusion. Assessment of patency and viability in open-chested dogs. J Clin Invest. 1985; 75: 1131–1137.
Goldstein RA. Rubidium-82 kinetics after coronary occlusion: Temporal relation of net myocardial accumulation and viability in open-chested dogs. J Nucl Med. 1986; 27: 1456–1461.
Herrero P, Markham J, Shelton ME, Weinheimer CJ, Bergmann SR. Noninvasive quantification of regional myocardial perfusion with rubidium-82 and positron emission tomography. Exploration of a mathematical model. Circulation. 1990; 82: 1377–1386.
Lin JW, Laine AF, Akinboboye O, Bergmann SR. Use of wavelet transforms in analysis of time-activity data from cardiac PET. J Nucl Med. 2001; 42: 194–200.
Lin JW, Sciacca RR, Chou RL, Laine AF, Bergmann SR. Quantification of myocardial perfusion in human subjects using 82Rb and wavelet-based noise reduction. J Nucl Med. 2001; 42: 201–208.
Green MA, Mathias CJ, Welch MJ, et al. Copper-62-labeled pyruvaldehyde bis(N4methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med. 1990; 31: 1989–1996.
Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Kinetics of copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. J Nucl Med. 1989; 30: 1843–1847.
Marshall R, Leidholdt EJ, Zhang D, Barnett C. Technetium-99m hexakis 2-methoxy-2isobutyl isonitrile and thallium-201 extraction, washout, and retention at varying coronary flow rates in rabbit heart. Circulation. 1990; 82: 998–1007.
Beanlands RS, Muzik O, Mintun M, et al. The kinetics of copper-62-PTSM in the normal human heart. J Nucl Med. 1992; 33: 684–690.
Wallhaus TR, Lacy J, Stewart R, et al. Copper-62-pyruvaldehyde bis(N-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans. J Nucl Cardiol. 2001; 8: 67–74.
Herrero P, Markham J, Weinheimer CJ, et al. Quantification of regional myocardial perfusion with generator-produced 62Cu-PTSM and positron emission tomography. Circulation. 1993; 87: 173–183.
Mélon P, Brihaye C, Degueldre C, et al. Myocardial kinetics of potassium-38 in humans and comparison with Copper-62-PTSM. J Nucl Med. 1994; 35: 1116–1122.
Poe ND. Comparative myocardial uptake and clearance characteristics of potassium and cesium. J Nucl Med. 1972; 13: 557–560.
Chan SY, Brunken RC, Phelps ME, Schelbert HR. Use of the metabolic tracer carbon11-acetate for evaluation of regional myocardial perfusion. JNucl Med. 1991; 32: 665–672.
Wolpers HG, Burchert W, van den Hoff J, Weinhardt R, Meyer GJ, Lichtlen PR. Assessment of myocardial viability by use of 11C-acetate and positron emission tomography. Threshold criteria of reversible dysfunction. Circulation. 1997; 95: 1417–1424.
Sun KT, Yeatman LA, Buxton DB, et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med. 1998; 39: 272–280.
Sciacca RR, Akinboboye O, Chou RL, Epstein S, Bergmann SR. Measurement of myocardial blood flow with PET using 1–11C-acetate. J Nucl Med. 2001; 42: 63–70.
Nickles R, Nunn A, Stone C, Christian B. Technetium-94m-teboroxime: synthesis, dosimetry and initial PET imaging studies. J Nucl Med. 1993; 34: 1058–1066.
Stone C, Christian B, Nickles R, Perlman S. Technetium 94m-labeled methoxyisobutyl isonitrile: Dosimetry and resting cardiac imaging with positron emission tomography. J Nucl Cardiol. 1994; 1: 425–433.
Nagamachi S, Czernin J, Kim AS, et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med. 1996; 37: 1626–1631.
Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 150-labeled water and PET. J Nucl Med. 1999; 40: 1848–1856.
Iida H, Yokoyama I, Agostini D, et al. Quantitative assessment of regional myocardial blood flow using oxygen-15-labelled water and positron emission tomography: a multicentre evaluation in Japan. Eur J Nucl Med. 2000; 27: 192–201.
Marcus M, Kerber R, Erhardt J, Falsetti H, Davis D, Abboud F. Spatial and temporal heterogeneity of left ventricular perfusion in awake dogs. Am Heart J. 1977; 94: 748–754.
King R, Bassingthwaighte J, Hales J, Rowell L. Stability of heterogeneity of myocardial blood flow in normal awake baboons. 1985; 57: 285–295.
Gould KL, Goldstein RA, Mullani NA, et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82. J Am Coll Cardiol. 1986; 7: 775–789.
Demer LL, Gould KL, Goldstein RA, et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation. 1989; 79: 825–835.
Schelbert HR, Wisenberg G, Phelps ME, Gould KL, Henze E, Hoffman EJ, Gomes A, Kuhl DE. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol. 1982; 49: 1197–1207.
Yonekura Y, Tamaki N, Senda M, Nohara R, Kambara H, Konishi Y, Koide H, Kureshi SA, Saji H, Ban T, et al. Detection of coronary artery disease with 13N-ammonia and high-resolution positron-emission computed tomography. Am Heart J. 1987; 113: 645–654.
Gerber BL, Melin JA, Bol A, et al. Nitrogen-13- and oxygen-15-water estimates of absolute myocardial perfusion in left ventricular ischemic dysfunction. J Nod Med. 1998; 39: 1655–1662.
Opie LH. Metabolism of the heart in health and disease. I. Am Heart J. 1968; 76: 685–698.
Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981; 23: 321–336.
Bing RJ. The metabolism of the heart. In: Harvey Society of NY ed. Harvey Lecture Series. New York: Academic Press; 1954: 27–70.
Keul J, Doll E, Steim H, Fleer U, Reindell H. Über den Stoffwechsel des menschlichen Herzens. III. Der oxidative Stoffwechsel des menschlichen Herzens unter verschiedened Arbeitsbedingungen II. Pflugers Archiv Gesamte Physiol Menschen Tiere. 1965; 282: 43–53.
Keul J, Doll E, Steim H, Homburger H, Kern H, Reindell H. Uber den Stoffwechsel des menschlichen Herzens. I. Substratversorgung des gesunden Herzens in Ruhe, während and nach körperlicher Arbeit. Pflugers Archiv Gesamte Physiol Menschen Tiere. 1965; 282: 1–27.
Randle RJ, Garland BP, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet. 1963; 1: 785–789.
Holmberg S, Serzysko W, Varnauskas E. Coronary circulation during heavy exercise in control subjects and patients with coronary heart disease. Acta Med Scand. 1971; 190: 465–480.
Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest. 1985; 76: 1819–1827.
Yamamoto Y, de Silva R, Rhodes CG, et al. Noninvasive quantification of regional myocardial metabolic rate of oxygen by 1502 inhalation and positron emission tomography. Experimental validation. Circulation. 1996; 94: 808–816.
Iida H, Rhodes CG, Araujo LI, et al. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 1502 inhalation and positron emission tomography. Theory, error analysis, and application in humans. Circulation. 1996; 94: 792–807.
Laine H, Katoh C, Luotolahti M, et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation. 1999; 100: 2425–2430.
Takala TO, Nuutila P, Katoh C, et al. Myocardial blood flow, oxygen consumption, and fatty acid uptake in endurance athletes during insulin stimulation. Am J Physiol. 1999; 277: E585 - E590.
Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation. 1987; 76: 687–696.
Brown MA, Myears DW, Bergmann SR. Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. J Am Coll Cardiol. 1988; 12: 1054–1063.
Buxton DB, Schwaiger M, Nguyen A, Phelps ME, Schelbert HR. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circulat Res. 1988; 63: 628–634.
Brown MA, Myears DW, Bergmann SR. Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization. J Nucl Med. 1989; 30: 187–193.
Buxton DB, Nienaber CA, Luxen A, et al. Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [1–11C]acetate and dynamic positron emission tomography. Circulation. 1989; 79: 134–142.
Armbrecht JJ, Buxton DB, Schelbert HR. Validation of [1–11C1 acetateas a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation. 1990; 81: 1594–1605.
Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR. Regional myocardial oxygen consumption determined noninvasively in humans with [1–11C]acetate and dynamic positron tomography. Circulation. 1989; 80: 863–872.
Henes CG, Bergmann SR, Walsh MN, Sobel BE, Geltman EM. Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate. J Nucl Med. 1989; 30: 1489–1499.
Ng CK, Huang SC, Schelbert HR, Buxton DB. Validation of a model for [1–11C]acetate as a tracer of cardiac oxidative metabolism. Am J Physiol. 1994; 266: H1304 - H1315.
Sun KT, Chen K, Huang SC, et al. Compartment model for measuring myocardial oxygen consumption using [1–11C]acetate. J Nucl Med. 1997; 38: 459–466.
Ukkonen H, Knuuti J, Katoh C, et al. Use of [11C1 acetate and [150]02 PET for the assessment of myocardial oxygen utilization in patients with chronic myocardial infarction. Eur J Nucl Med. 2001; 28: 334–339.
Schön HR, Schelbert HR, Najafi A, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. II. Kinetics of C-11 palmitic acid in acutely ischemic myocardium. Am Heart J. 1982; 103: 548–561.
Fox KA, Abendschein DR, Ambos HD, Sobel BE, Bergmann SR. Efflux of metabolized and nonmetabolized fatty acid from canine myocardium. Implications for quantifying myocardial metabolism tomographically. Circulat Res. 1985; 57: 232–243.
Rosamond TL, Abendschein DR, Sobel BE, Bergmann SR, Fox KA. Metabolic fate of radiolabeled palmitate in ischemic canine myocardium: implications for positron emission tomography. J Nucl Med. 1987; 28: 1322–1329.
Wyns W, Schwaiger M, Huang SC, et al. Effects of inhibition of fatty acid oxidation on myocardial kinetics of 11C-labeled palmitate. Circulat Res. 1989; 65: 1787–1797.
Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med. 1996; 37: 1723–1730.
Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002; 40: 271–277.
Stone CK, Pooley RA, DeGrado TR, et al. Myocardial uptake of the fatty acid analog 14fluorine-18-fluoro-6-thia-heptadecanoic acid in comparison to beta-oxidation rates by tritiated palmitate. J Nucl Med. 1998; 39: 1690–1696.
DeGrado TR, Wang S, Holden JE, Nickles RJ, Taylor M, Stone CK. Synthesis and preliminary evaluation of (18)F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation. Nucl Med Biol. 2000; 27: 221–231.
Renstrom B, Rommelfanger S, Stone CK, et al. Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia. J Nucl Med. 1998; 39: 1684–1689.
Mäki MT, Haaparanta M, Nuutila P, et al. Free fatty acid uptake in the myocardium and skeletal muscle using fluorine-18-fluoro-6-thia-heptadecanoic acid. J Nucl Med. 1998; 39: 1320–1327.
Taylor M, Wallhaus TR, Degrado TR, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluoro-6-thia-heptadecanoic acid. J Nucl Med. 2001; 42: 55–62.
Hawkins RA, Mans AM, Davis DW, Vina JR, Hibbard LS. Cerebral glucose use measured with [14C]glucose labeled in the 1, 2, or 6 position. Am J Physiol. 1985; 248: C170 - C176.
Stone-Elander S, Halldin C, Langstrom B, et al. Production method for [11C]-D-glucose labeled in carbon-1 for positron emission tomography of glucose metabolism. Acta Radiol Suppl. 1991; 376: 102–103.
Dence CS, Powers WJ, Welch MJ. Improved synthesis of 1-[11C]D-glucose. Appl Radiat Isot. 1993; 44: 971–980.
Herrero P, Weinheimer CJ, Dence C, Oellerich WF, Gropler RJ. Quantification of myocardial glucose utilization by PET and 1-carbon-11-glucose. JNucl Cardiol. 2002; 9: 5–14.
Phelps ME, Hoffman EJ, Selin C, et al. Investigation of [18F]2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978; 19: 1311–1319.
Krivokapich J, Huang SC, Selin CE, Phelps ME. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol. 1987; 252: H777 - H787.
Sokoloff L, Reivich M, Kennedy C, et al. The [14C1-deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977; 28: 897–916.
Ratib O, Phelps ME, Huang SC, Henze E, Selin CE, Schelbert HR. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med. 1982; 23: 577–586.
Gambhir SS, Schwaiger M, Huang SC, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med. 1989; 30: 359–366.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1985; 5: 584–590.
Schneider CA, Nguyen VT, Taegtmeyer H. Feeding and fasting determine postischemic glucose utilization in isolated working rat hearts. Am J Physiol. 1991; 260: H542 - H548.
Russell RR III, Nguyen VT, Mrus JM, Taegtmeyer H. Fasting and lactate unmask insulin responsiveness in the isolated working rat heart. Am J Physiol. 1992; 263: E556 - E561.
Russell RR III, Cline GW, Guthrie PH, Goodwin GW, Shulman GI, Taegtmeyer H. Regulation of exogenous and endogenous glucose metabolism by insulin and acetoacetate in the isolated working rat heart. A three tracer study of glycolysis, glycogen metabolism, and glucose oxidation. J Clin Invest. 1997; 100: 2892–2899.
Doenst T, Taegtmeyer H. Complexities underlying the quantitative determination of myocardial glucose uptake with 2-deoxyglucose. J Molec Cell Cardiol. 1998; V30: 1595–1604.
Botker HE, Goodwin GW, Holden JE, Doenst T, Gjedde A, Taegtmeyer H. Myocardial glucose uptake measured with fluorodeoxyglucose: A prospect method to account for variable lumped constants. J Nucl Med. 1999; 40: 1186–1196.
Hariharan R, Bray M, Ganim R, Doenst T, Goodwin GW, Taegtmeyer H. Fundamental limitations of [F-18]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation. 1995; 91: 2435–2444.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237: E214 - E223.
Hicks R, von Dahl J, Lee K, Herman W, Kalff V, Schwaiger M. Insulin-glucose clamp for standardization of metabolic conditions during F-18 fluoro-deoxyglucose PET imaging. JAm Coll Cardiol. 1991; 17: 381A.
Meaki M, Luotolahti M, Nuutila P, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation. 1996; 93: 1658–1666.
Gerber BL, Ordoubadi FF, Wijns W, et al. Positron emission tomography using(18)Ffluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter Study on Use of (18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability. Eur Heart J. 2001; 22: 1691–1701.
Bax JJ, Visser FC, Poldermans D, et al. Feasibility, safety and image quality of cardiac FDG studies during hyperinsulinaemic-euglycaemic clamping. Eur J Nucl Med. 2002; 29: 452–457.
Nuutila P, Knuuti M, Raitakari M, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol. 1994; 267: E941 - E946.
Stone C, Holden J, Stanley W, Perlman S. Effect of nicotinic acid on exogenous myocardial glucose utilization. J Nucl Med. 1995; 36: 996–1002.
Vitale GD, deKemp RA, Ruddy TD, Williams K, Beanlands RSB. Myocardial glucose utilization and optimization of 18F-FDG PET imaging in patients with non-insulindependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med. 2001; 42: 1730–1736.
Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res. 2001; 50: 151–161.
Krivokapich J, Huang SC, Schelbert HR. Assessment of the effects of dobutamine on myocardial blood flow and oxidative metabolism in normal human subjects using nitrogen-13 ammonia and carbon-11 acetate. Am J Cardiol. 1993; 71: 1351–1356.
Senneff MJ, Geltman EM, Bergmann SR. Noninvasive delineation of the effects of moderate aging on myocardial perfusion [published erratum appears in J Nucl Med 1992; 33(2):201] [see comments]. J Nucl Med. 1991; 32: 2037–2042.
Uren NG, Camici PG, Melin JA, et al. Effect of aging on myocardial perfusion reserve. J Nucl Med. 1995; 36: 2032–2036.
Kalliokoski KK, Nuutila P, Laine H, et al. Myocardial perfusion and perfusion reserve in endurance-trained men. Med Sci Sports Exerc. 2002; 34: 948–953.
Radvan J, Choudhury L, Sheridan DJ, Camici PG. Comparison of coronary vasodilator reserve in elite rowing athletes versus hypertrophic cardiomyopathy. Am J Cardiol. 1997; 80: 1621–1623.
Brown BG, Josephson MA, Peterson RB, et al. Intravenous dipyridamole combined with isometric handgrip for near maximal acute increase in coronary flow in patients with coronary artery disease. Am J Cardiol. 1981; 48: 1077–1085.
Czernin J, Auerbach M, Sun KT, Phelps M, Schelbert HR. Effects of modified pharmacologic stress approaches on hyperemic myocardial blood flow. J Nucl Med. 1995; 36: 575–580.
Chan SY, Brunken RC, Czernin J, et al. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol. 1992; 20: 979–985.
Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schäfers KP, Löscher TF, Camici PG. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation. 2000; 102: 1233–1238.
Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve. Circulation. 1998; 98: 1291–1296.
Iwado Y, Yoshinaga K, Furayama H, et al. Decreased endothelium-dependent coronary vosmotion in healthy young smokers. Eur J Nucl Med. 2002; 29: 984–990.
Tadamura E, Iida H, Matsumoto K, et al. Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men. JAm Coll Cardiol. 2001; 37: 130–136.
Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 1988; 77: 43–52.
Zeiher AM, Drexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium [see comments]. J Am Coll Cardiol 1989; 14: 1181–1190.
Zeiher AM, Drexler H. Coronary hemodynamic determinants of epicardial artery vasomotor responses during sympathetic stimulation in humans. Basic Res Cardiol. 1991; 86: 203–213.
Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994; 89: 2525–2532.
Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991; 84: 1984–1992.
Campisi R, Czernin J, Schöder H, et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation. 1998; 98: 119–125.
Campisi R, Czernin J, Schöder H, Sayre JW, Schelbert HR. L-Arginine normalizes coronary vasomotion in long-term smokers. Circulation. 1999; 99: 491–497.
Raitakari OT, Toikka J, Laine H, Viikari J, Knuuti J, Hartiala J. Reduced myocardial flow reserve does not impair exercise capacity in asymptomatic men. Am J Cardiol. 1999;84: 1253–1255, A8.
Smits P, Williams S, Lipson D, Banitt P, Rongen G, Creager M. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation. 1995; 92: 2135–2141.
Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation. 2001; 104: 2305–2310.
Böttcher M, Czernin J, Sun KT, Phelps ME, Schelbert HR. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med. 1995; 36: 2016–2021.
Müller P, Czernin J, Choi Y, et al. Effect of exercise supplementation during adenosine infusion on hyperemic blood flow and flow reserve. Am Heart J. 1994; 128: 52–60.
Böttcher M, Czernin J, Sun K, Phelps ME, Schelbert HR. Effect of beta 1 adrenergic receptor blockade on myocardial blood flow and vasodilatory capacity. J Nucl Med. 1997; 38: 442–446.
Laine H, Nuutila P, Luotolahti M, Meyer C, Ronnemaa T, Knuuti J. Insulin-induced increment of coronary flow reserve is not abolished by dexamethasone in healthy young men. J Am Coll Cardiol. 2000; 35: 419A.
Sundell J, Nuutila P, Laine H, et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes. 2002; 51: 1125–1130.
Marcus M. Methods of calculating coronary vascular resistance. The Coronary Circulation in Health and Disease. New York: McGraw-Hill; 1983: 107–109.
Tamaki N, Magata Y, Takahashi N, et al. Oxidative metabolism in the myocardium in normal subjects during dobutamine infusion. Eur J Nucl Med. 1993; 20: 231–237.
Hicks R, Kalff V, Savas V, Starling M, Schwaiger M. Assessment of right ventricular oxidative metabolism by positron emission tomography with C-11 acetate in aortic valve disease. Am J Cardiol. 1991; 67: 753–757.
Schelbert HR, Henze E, Sochor H, et al. Effects of substrate availability on myocardial C-11 palmitate kinetics by positron emission tomography in normal subjects and patients with ventricular dysfunction. Am Heart J. 1986; 111: 1055–1064.
Grover-McKay M, Schelbert HR, Schwaiger M, et al. Identification of impaired metabolic reserve by atrial pacing in patients with significant coronary artery stenosis. Circulation. 1986; 74: 281–292.
Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans [see comments]. J Nucl Med. 1990; 31: 1749–1756.
Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med. 1993; 20: 308–318.
Knuuti M, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during Positron Emission Tomography. J Nucl Med. 1992; 33: 1255–1262.
Schelbert HR, Henze E, Keen R, et al. C-11 palmitate for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. IV. In vivo evaluation of acute demand-induced ischemia in dogs. Am Heart J. 1983; 106: 736750.
Nuutila P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest. 1992; 89: 1767–1774.
Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. Am J Cardiol. 1979; 43: 200–208.
Schelbert HR, Phelps ME, Hoffman EJ, Huang SC, Selin CE, Kuhl DE. Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography. Am J Cardiol. 1979; 43: 209–219.
Tamaki N, Yonekura Y, Senda M, et al. Myocardial positron computed tomography with 13N ammonia at rest and during exercise. Eur J Nucl Med. 1985; 11: 246–251.
Tamaki N, Yonekura Y, Senda M, et al. Value and limitation of stress thallium-201 single photon emission computed tomography: comparison with nitrogen-13 ammonia positron tomography. I Nuel Med. 1988; 29: 1181–1188.
Go RT, Marwick TH, Maclntyre WJ, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease [see comments]. J Nucl Med. 1990; 31: 1899–1905.
Stewart R, Schwaiger M, Molina E, et al. Comparison of rubidium-82 Positron Emission Tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol. 1991; 67: 1303–1310.
Simone G, Mullani N, Page D, Anderson B Sr. Utilization statistics and diagnostic accuracy of a nonhospital-based positron emission tomography center for the detection of coronary artery disease using rubidium-82. Am J Physiol Imag. 1992; 7: 203–209.
Williams B, Millani N, Jansen D, Anderson B. A retrospective study of the diagnostic accuracy of a community hospital-based PET center for the detection of coronary artery disease using rubidium-82. J Nucl Med. 1994; 35: 1586–1592.
Zijlstra F, Fioretti P, Reiber JH, Serruys PW. Which cineangiographically assessed anatomic variable correlates best with functional measurements of stenosis severity? A comparison of quantitative analysis of the coronary cineangiogram with measured coronary flow reserve and exercise/redistribution thallium-201 scintigraphy. J Am Coll Cardiol. 1988; 12: 686–691.
Flamm SD, Khanna S, Dicarli M, Phelps M, Schelbert HR, Maddahi J. Prognostic significance of normal adenosine stress myocardial perfusion PET study in patients presenting with chest pain. J Nod Med. 1994; 35: 60 P.
Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol. 1997; 80: 865–870.
Marwick TH, Shan K, Go RT, Maclntyre WJ, Lauer MS. Use of positron emission tomography for prediction of perioperative and late cardiac events before vascular surgery. Am Heart J. 1995; 130: 1196–1202.
Sdringola S, Patel D, Gould KL. High prevalence of myocardial perfusion abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. Circulation. 2001; 103: 496–501.
Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification [see comments]. JAMA. 1995; 274: 894–901.
Sambuceti G, Parodi O, Marcassa C, et al. Alteration in regulation of myocardial blood flow in one-vessel coronary artery disease determined by positron emission tomography. Am J Cardiol. 1993; 72: 538–543.
Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995; 91: 1944–1951.
Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation. 1999; 99: 475–481.
Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med. 1994; 330: 1782–1788.
Beanlands RS, Muzik O, Melon P, et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity. JAm Coll Cardiol. 1995; 26: 1465–1475.
Muzik O, Duvernoy C, Beanlands RS, et al. Assessment of diagnostic performance of quantitative flow measurements in normal subjects and patients with angiographically documented coronary artery disease by means of nitrogen-13 ammonia and positron emission tomography. JAm Coll Cardiol. 1998; 31: 534–540.
Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 1974; 33: 87–94.
De Bruyne B, Baudhuin T, Melin J, et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994; 89: 1013–1022.
Krivokapich J, Czernin J, Schelbert HR. Dobutamine positron emission tomography: absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease. JAm Coll Cardiol. 1996; 28: 565–572.
Vanoverschelde JL, Wijns W, Depré C, et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium [see comments]. Circulation. 1993; 87: 1513–1523.
Holmvang G, Fry S, Skopicki HA, et al. Relation between coronary “steal” and contractile function at rest in collateral-dependent myocardium of humans with ischemic heart disease. Circulation. 1999; 99: 2510–2516.
Akinboboye 00, Idris 0, Chou RL, Sciacca RR, Cannon PJ, Bergmann SR. Absolute quantitation of coronary steal induced by intravenous dipyridamole. J Am Coll Cardiol. 2001; 37: 109–116.
Kosa I, Blasini R, Schneider-Eicke J, et al. Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol. 1999; 34: 1036–1041.
Uren NG, Crake T, Lefroy DC, DeSilva R, Davies GJ, Maseri A. Delayed recovery of coronary resistive vessel function after coronary angioplasty. JAm Coll Cardiol. 1993; 21: 612–621.
Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms [see comments]. N Engl J Med. 1993; 328: 1659–1664.
Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 1994; 90: 808–817.
Duvernoy CS, Meyer C, Seifert-Klauss V, et al. Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects. J Am Coll Cardiol. 1999; 33: 463–470.
Pitkänen OP, Raitakari OT, Niinikoski H, et al. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. JAm Coll Cardiol. 1996; 28: 1705–1711.
Yokoyama I, Murakami T, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Ornata M. Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med. 1996; 37: 1937–42.
Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Ornata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation. 1996; 94: 3232–3238.
Yokoyama I, Ohtake T, Momomura S, et al. Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia. JAm Coll Cardiol. 1998; 31: 1568–1574.
Pitkänen OP, Nuutila P, Raitakari OT, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation. 1999; 99: 1678–1684.
Kaufmann PA, Gnecchi-Ruscone T, Schäfers KP, Löscher TF, Camici PG. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. JAm Coll Cardiol. 2000; 36: 103–109.
Yokoyama I, Ohtake T, Momomura S, et al. Altered myocardial vasodilatation in patients with hypertriglyceridemia in anatomically normal coronary arteries. Arterioscler Thromb Vasc BioL 1998; 18: 294–299.
Pitkanen OP, Raitakari OT, Ronnemaa T, et al. Influence of cardiovascular risk status on coronary flow reserve in healthy young men. Am J Cardiol. 1997; 79: 1690–1692.
Laine H, Raitakari OT, Niinikoski H, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. JAm Coll Cardiol. 1998; 32: 147–153.
Yokoyama I, Momomura S, Ohtake T, et al. Reduced myocardial flow reserve in noninsulin-dependent diabetes mellitus [see comments]. J Am Coll Cardiol. 1997; 30: 1472 1477.
Pitkänen OP, Nuutila P, Raitakari OT, et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes. 1998; 47: 248–254.
Yokoyama I, Ohtake T, Momomura S, et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes. 1998; 47: 119–124.
Yokoyama I, Yonekura K, Ohtake T, et al. Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease. J Nucl Med. 2000; 41: 978–985.
Bache RJ. Vasodilator reserve: a functional assessment of coronary health [editorial; comment]. Circulation. 1998; 98: 1257–1260.
Schwaiger M, Kalif V, Rosenspire K, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography [see comments]. Circulation. 1990; 82: 457–464.
Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med. 1997; 336: 1208–1215.
Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999; 100: 813–819.
Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation. 1998; 98: 961–968.
Schöder H, Silverman DH, Campisi R, et al. Regulation of myocardial blood flow response to mental stress in healthy individuals. Am J Physiol Heart Circ Physiol. 2000; 278: H360 - H366.
Schöder H, Silverman DH, Campisi R, et al. Effect of mental stress on myocardial blood flow and vasomotion in patients with coronary artery disease. JNucl Med. 2000; 41: 11–16.
Bottcher M, Madsen MM, Refsgaard J, et al. Peripheral flow response to transient arterial forearm occlusion does not reflect myocardial perfusion reserve. Circulation. 2001; 103: 1109–1114.
Gould KL, Nakagawa Y, Nakagawa K, et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Circulation. 2000; 101: 1931–1939.
Hernandez-Pampaloni M, Keng FYY, Kudo T, Sayre JS, Schelbert HR. Abnormal longitudinal base to apex myocardial perfusion gradient by quantitative blood flow measurements in patients with coronary risk factors. Circulation. 2001; 104: 527–532.
De Bruyne B, Hersbach F, Pijls NH, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but “Normal” coronary angiography. Circulation. 2001; 104: 2401–2406.
Smart FW, Ballantyne CM, Cocanougher B, et al. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991; 67: 243247.
Hosenpud JD. Noninvasive diagnosis of cardiac allograft rejection. Another of many searches for the grail [editorial; comment]. Circulation. 1992; 85: 368–371.
Chan SY, Kobashigawa J, Stevenson LW, Brownfield E, Brunken RC, Schelbert HR. Myocardial blood flow at rest and during pharmacological vasodilation in cardiac transplants during and after successful treatment of rejection. Circulation. 1994; 90: 204–212.
Senneff MJ, Hartman J, Sobel BE, Geltman EM, Bergmann SR. Persistence of coronary vasodilator responsivity after cardiac transplantation. Am J Cardiol. 1993; 71: 333–338.
Kofoed KF, Czernin J, Johnson J, et al. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion. Circulation. 1997; 95: 600–606.
Czernin J, Barnard RJ, Sun KT, et al. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation. 1995; 92: 197204.
Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease [see comments]. N Engl J Med. 2000; 342: 454–460.
Smith SC, Jr. Risk-reduction therapy: the challenge to change. Presented at the 68th Scientific Sessions of the American Heart Association, November 13, 1995, Anaheim, California. Circulation. 1996; 93: 2205–2211.
Janatuinen T, Laaksonen R, Vesalainen R, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol. 2001; 38: 561–568.
Yokoyama I, Yonekura K, Inoue Y, Ohtomo K, Nagai R. Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol. 2001; 8: 445–451.
Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation. 1999; 99: 2871–2875.
Mellwig KP, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis. 1998; 139: 173–178.
John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 1998; 98: 211–216.
Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129–1135.
Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. JAm Coll Cardiol. 1999; 33: 234–241.
Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999; 100: 2131–2134.
Yokoyama I, Momomura S, Ohtake T, et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation. 1999; 100: 117–122.
Kurz S, Harrison DG. Insulin and the arginine paradox [editorial]. J Clin Invest. 1997; 99: 369–370.
Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98: 1842–1847.
Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20: 1557–1564.
Pampaloni MH, Hsueh WA, Quinones M, Sayre JS, Schelbert HR. PET determined myocardial blood flow demonstrates abnormal coronary vasomotion in insulin resistance without diabetes. J Nucl Med. 2000; 41: 44 P.
Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol. 1999; 84: 21J - 24J.
Duvernoy CS, Rattenhuber J, Seifert-Klauss V, Bengel F, Meyer C, Schwaiger M. Myocardial blood flow and flow reserve in response to short-term cyclical hormone replacement therapy in postmenopausal women. J Gend Specif Med. 2001; 4: 21–27.
Peterson LR, Eyster D, Davila-Roman VG, et al. Short-term oral estrogen replacement therapy does not augment endothelium-independent myocardial perfusion in postmenopausal women. Am Heart J. 2001; 142: 641–647.
Campisi R, Nathan L, Pampaloni MH, Schoder H, Sayre JW, Chaudhuri G, Schelbert HR. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation. 2002; 105: 425–430.
Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000; 102: 846–851.
Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899–906.
Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Longterm follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948–954.
Choudhury L, Rosen SD, Patel D, Nihoyannopoulos P, Camici PG. Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography. Eur Heart J. 1997; 18: 108–116.
Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991; 17: 879–886.
Choudhury L, Elliott P, Rimoldi O, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Bas Res Cardiol. 1999; 94: 49–59.
Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurea S, Bonow RO. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophie cardiomyopathy. Am J Cardiol. 1993; 72: 199–204.
Tadamura E, Yoshibayashi M, Yonemura T, et al. Significant regional heterogeneity of coronary flow reserve in paediatric hypertrophic cardiomyopathy. Eur J Nucl Med. 2000; 27: 1340–1348.
Drzezga A, Blasini R, Ziegler S, et al. Quantitative flow measurement using N-13 ammonia positron emission tomography during rest and stress by cold pressor test in normal subjects and patients with dilated cardiomyopathy. J Nucl Med. 1995; 36: 3 P.
Weismueller S, Czernin J, Sun KT, Fung C, Phelps ME, Schelbert HR. Reduced coronary vasodilator capacity in idiopathic dilated cardiomyopathy. J Nucl Med. 1996; 37: 82P - 83 P.
van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000; 35: 19–28.
Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002; 105: 186–193.
Drzezga AE, Blasini R, Ziegler SI, Bengel FM, Picker W, Schwaiger M. Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2000; 41: 837–844.
Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate-comparison between the normal and failing human heart. Eur J Nucl Med. 2000; 27: 319–326.
Wolpers HG, Buck A, Nguyen N, et al. An approach to ventricular efficiency by use of carbon 11-labeled acetate and positron emission tomography. JNucl Cardiol. 1994; 1: 262–269.
Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000; 102: 2070–2075.
Geltman EM, Smith JL, Beecher D, Ludbrook PA, Ter-Pogossian MM, Sobel BE. Altered regional myocardial metabolism in congestive cardiomyopathy detected by positron tomography. Am J Med. 1983; 74: 773–785.
Eisenberg JD, Sobel BE, Geltman ED. Differentiation of ischemic from nonischemic cardiomyopathy with positron emission tomography. Am J Cardiol. 1987; 59: 1410–1414.
Sochor H, Schelbert H, Schwaiger M, Henze E, Phelps M. Studies of fatty acid metabolism with positron emission tomography in patients with cardiomyopathy. Eur J Nucl Med. 1986; 12: S66 - S69.
Vaghaiwalla Mody F, Brunken R, Warner-Stevenson L, Nienaber C, Phelps M, Schelbert H. Differentiating cardiomyopathy of coronary artery disease from non-ischemic dilated cardiomyopathy utilizing positron tomography. J Am Coll Cardiol. 1991; 17: 373–383.
Opie LH, Owen P, Riemersma RA. Relative rates of oxidation of glucose and free fatty acids by ischemic and non-ischemic myocardium after coronary artery ligation in the dog. Eur J Clin Invest. 1973; 3: 419–435.
Schelbert HR, Phelps ME, Selin C, Marshall RC, Hoffman EJ, Kuhl DE. Regional myocardial ischemia assessed by 18Fluoro-2-deoxyglucose and positron emission computed tomography. In: Kreuzer H, Parmley WW, Rentrop P, Heiss HW, eds. Quantification of Myocardial Ischemia. New York: Gehard Witzstrock Publishing House; 1980: 437–447.
Marshall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E, Schelbert HR. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation. 1983; 67: 766–78.
Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986; 314: 884–888.
vom Dahl J, Altehoefer C, Sheehan F, et al. Recovery of regional left ventricular dysfunction after coronary revascularization: Impact of myocardial viability assessed by nuclear imaging and vessel patency at follow-up angiography. J Am Coll Cardiol. 1996; 28: 948–958.
Maes A, Flameng W, Nuyts J, et al. Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings. Circulation. 1994; 90: 735–745.
Depré C, Vanoverschelde JL, Melin JA, et al. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol. 1995; 268: H1265 - H1275.
Gewirtz H, Fischman A, Abraham S, Gilson M, Strauss H, Alpert N. Positron emission tomographic measurements of absolute regional myocardial blood flow permits identification of nonviable myocardium in patients with chronic myocardial infarction. J Am Coll Cardiol. 1994; 23: 851–859.
Duvernoy CS, vom Dahl J, Laubenbacher C, Schwaiger M. The role of nitrogen 13 ammonia positron emission tomography in predicting functional outcome after coronary revascularization. J Nucl Cardiol. 1995; 2: 499–506.
Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol. 1999; 34: 163–169.
Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose [see comments]. Circulation. 1991; 83: 26–37.
Knuuti M, Saraste M, Nuutila P, Härkönen R, Wegelius U, Haapanen A. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J. 1994; 127: 785–796.
Baer FM, Voth E, Deutsch HJ, Schneider CA, Schicha H, Sechtem U. Assessment of viable myocardium by dobutamine transesophageal echocardiography and comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. JAm Coll Cardiol. 1994; 24: 343–353.
Buvat I, Bartlett M, Srinivasan G, et al. Can gated FDG PET assess LV function as well as gated bloodpool SPECT? J Nucl Med. 1996; 37: 39 P.
Buvat I, Kitsiou A, Srinivasan G, Dilsizian V, Bacharach S. Relationship between metabolism and function in CAD patients using gated FDG PET. JNucl Med. 1996; 37: 161 P.
Fath-Ordoubadi F, Beatt KJ, Spyrou N, Camici PG. Efficacy of coronary angioplasty for the treatment of hibernating myocardium. Heart. 1999; 82: 210–216.
DePuey EG, Ghesani M, Schwartz M, Friedman M, Nichols K, Salensky H. Comparative performance of gated perfusion SPECT wall thickening, delayed thallium uptake, and F-18 fluorodeoxyglucose SPECT in detecting myocardial viability. J Nucl Cardiol. 1999; 6: 418–428.
Schöder H, Campisi R, Ohtake T, et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. JAm Coll Cardiol. 1999; 33: 1328–1337.
Erler H, Zaknun J, Donnemiller E, et al. One year’s clinical experience of 18F-FDG PET with a modified SPECT camera using molecular coincidence detection. Nucl Med Co m m u n. 1999; 20: 1009–1015.
Fukuchi K, Sago M, Nitta K, et al. Attenuation correction for cardiac dual-head gamma camera coincidence imaging using segmented myocardial perfusion SPECT. JNucl Med. 2000; 41: 919–925.
Nowak B, Zimny M, Schwarz ER, et al. Diagnosis of myocardial viability by dual-head coincidence gamma camera fluorine-18 fluorodeoxyglucose positron emission tomography with and without non-uniform attenuation correction. Eur J Nucl Med. 2000; 27: 1501–1508.
Di Bella EV, Kadrmas DJ, Christian PE. Feasibility of dual-isotope coincidence/singlephoton imaging of the myocardium. J Nucl Med. 2001; 42: 944–950.
Bax JJ, Cornel JH, Visser FC, et al. F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization. J Nucl Cardiol. 1997; 4: 302–308.
Bax JJ, Visser FC, Elhendy A, et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. J Nucl Med. 1999; 40: 1866–1873.
Gropler RJ, Geltman EM, Sampathkumaran K, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol. 1992; 20: 569–577.
Gropler RJ, Siegel BA, Sampathkumaran K, et al. Dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. JAm Coll Cardiol. 1992; 19: 989–997.
Rubin PJ, Lee DS, Davila-Roman VG, et al. Superiority of C-11 acetate compared with F-18 fluorodeoxyglucose in predicting myocardial functional recovery by positron emission tomography in patients with acute myocardial infarction. Am J Cardiol. 1996; 78: 1230–1235.
Hata T, Nohara R, Fujita M, et al. Noninvasive assessment of myocardial viability by positron emission tomography with 11C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Circulation. 1996; 94: 1834–1841.
Wolpers HG, Burchert W, van den Hoff J, Weinhardt R, Meyer GJ, Lichtlen PR. Assessment of myocardial viability by use of 11C-acetate and positron emission tomography. Threshold criteria of reversible dysfunction. Circulation. 1997; 95: 1417–1424.
Camici P, Araujo LI, Spinks T, et al. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Circulation. 1986; 74: 81–88.
Schwaiger M, Schelbert HR, Ellison D, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol. 1985; 6: 336–347.
Gerber BL, Wijns W, Vanoverschelde JL, et al. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: direct evidence for myocardial stunning in humans. JAm Coll Cardiol. 1999; 34: 1939–1946.
Schwaiger M. Time course of metabolic findings in coronary occlusion and reperfusion and their role for assessing myocardial salvage. Eur J Nucl Med. 1986;12 Suppl: S54–S58.
Bolli R. Myocardial `stunning’ in man. Circulation. 1992; 86: 1671–1691.
Barnes E, Baker CS, Dutka DP, et al. Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia. Heart. 2000; 83: 283–289.
Barnes E, Dutka DP, Khan M, Camici PG, Hall RJ. Effect of repeated episodes of reversible myocardial ischemia on myocardial blood flow and function in humans. Am J Physiol Heart Circ Physiol. 2002; 282: H1603 - H1608.
Barnes E, Hall RJ, Dutka DP, Camici PG. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol. 2002; 39: 420–427.
Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989; 117: 211–221.
Schulz R, Rose J, Martin C, Brodde O-E, Heusch G. Development of short-term myocardial hibernation-Its limitation by the severity of ischemia and inotropic stimulation. Circulation. 1993; 88: 684–695.
Fallavollita J, Bryan P, Gantry J. 18F-2-deoxyglucose deposition and regional flow in pigs with chronically dysfunctional myocardium: evidence for transmural variations in chronic hibernating myocardium. Circulation. 1997; 95: 1900–1909.
Fallavollita JA, Canty JM Jr. Differential 18F-2-deoxyglucose uptake in viable dysfunctional myocardium with normal resting perfusion: evidence for chronic stunning in pigs. Circulation. 1999; 99: 2798–2805.
Lim H, Fallavollita JA, Hard R, Kerr CW, Canty JM Jr. Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium. Circulation. 1999; 100: 2380–2386.
Shivalkar B, Flameng W, Szilard M, Pislaru S, Borgers M, Vanhaecke J. Repeated stunning precedes myocardial hibernation in progressive multiple coronary artery obstruction. J Am Coll Cardiol. 1999; V34: 2126–2136.
Schwaiger M, Brunken R, Grover-McKay M, et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol. 1986; 8: 800–808.
Fragasso G, Chierchia S, Lucignani G, et al. Time dependence of residual tissue viability after myocardial infarction assessed by [18F] fluorodeoxyglucose and positron emission tomography. Am J Cardiol. 1993; 72: 131G - 139G.
Fedele FA, Gewortz J, Capone RJ, Sharaf B, Most AS. Metabolic response to prolonged reduction of myocardial blood flow distal to a severe coronary artery stenosis. Circulation. 1988; 78: 729–735.
Camici PG, Wijns W, Borgers M, et al. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation. 1997; 96: 3205–3214.
Maes A, Flameng W, Borgers M, et al. Regional myocardial blood flow, glucose utilization and contractile function before and after revascularization and ultrastructural findings in patients with chronic coronary artery disease. Eur JNucl Med. 1995; 22: 1299–1305.
Maes A, Mortelmans L, Nuyts J, et al. Importance of flow/metabolism studies in predicting late recovery of function following reperfusion in patients with acute myocardial infarction. Eur Heart J. 1997; 18: 954–962.
Czernin J, Porenta G, Rosenquist G, et al. Loss of coronary perfusion reserve in PET ischemia. Circulation. 1991; 84: I1–47.
Pagano D, Bonser RS, Camici PG. Myocardial revascularization for the treatment of post-ischemic heart failure. Curr Opin Cardiol. 1999; 14: 506–509.
Pagano D, Fath-Ordoubadi F, Beatt KJ, Townend JN, Bonser RS, Camici PG. Effects of coronary revascularisation on myocardial blood flow and coronary vasodilator reserve in hibernating myocardium. Heart. 2001; 85: 208–212.
Sun KT, Czernin J, Krivokapich J, et al. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium [see comments]. Circulation. 1996; 94: 3146–3154.
Pasquet A, Robert A, D’Hondt AM, Dion R, Melin JA, Vanoverschelde JL. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation. 1999; 100: 141–148.
Pasquet A, Williams MJ, Secknus MA, Zuchowski C, Lytle BW, Marwick TH. Correlation of preoperative myocardial function, perfusion, and metabolism with postoperative function at rest and stress after bypass surgery in severe left ventricular dysfunction. Am J Cardiol. 1999; 84: 58–64.
Pasquet A, Lauer MS, Williams MJ, Secknus MA, Lytle B, Marwick TH. Prediction of global left ventricular function after bypass surgery in patients with severe left ventricular dysfunction. Impact of pre-operative myocardial function, perfusion, and metabolism [see comments]. Eur Heart J. 2000; 21: 125–136.
Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart. 1998; 79: 281–288.
Nagueh SF, Mikati I, Weilbaecher D, et al. Relation of the contractile reserve of hibernating myocardium to myocardial struture in humans. Circulation. 1999; 100: 490–496.
Bax JJ, Poldermans D, Visser FC, et al. Delayed recovery of hibernating myocardium after surgical revascularization: implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability. J Nucl Cardiol. 1999; 6: 685–687.
Schwarz ER, Schaper J, vom Dahl J, et al. Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol. 1996; 27: 1577–1585.
Pagano D, Camici PG. Relation of contractile reserve of hibernating myocardium to myo-cardial structure in humans. Circulation. 2000; 102: E189 - E190.
Stinson E, Billingham M. Correlative study of regional left ventricular histology and contractile function. Am J Cardiol. 1977; 39: 378–383.
Cabin HS, Clubbs KS, Vita N, Zaret BL. Regional dysfunction by equilibrium radionuclide angiography: A clinicopathologic study evaluating the relation of degree of dysfunction to the presence and extent of myocardial infarction. J Am Coll Cardiol. 1987; 10: 743–747.
Flameng W, Suy R, Schwarz F, et al. Ultrastructural correlates of left ventricular contraction abnormalities in patients with chronic ischemic heart disease: determinants of reversible segmental asynergy post-revascularization surgery. Am Heart J. 1981; 102: 846–857.
Schwarz E, Schaper J, vom Dahl J, et al. Myocardial hibernation is not sufficient to prevent morphological disarrangements with ischemic cell alterations and increased fibrosis. Circulation. 1994; 90: I - 378.
Schwaiger M, Sun D, Deeb G, et al. Expression of myocardial glucose transporter (GLUT) mRNAs in patients with advanced coronary artery disease (CAD). Circulation. 1994; 90: I - 113.
Brosius FC, III, Liu Y, Nguyen N, Sun D, Bartlett J, Schwaiger M. Persistent myocardial ischemia increases GLUT1 glucose transporter expression in both ischemic and nonischemic heart regions. J Molec Cell Cardiol. 1997; 29: 1675–1685.
Brosius FC, III, Nguyen N, Egert S, et al. Increased sarcolemmal glucose transporter abundance in myocardial ischemia. Am J Cardiol. 1997; 80: 77A - 84A.
Vogt AM, Nef H, Schaper J, et al. Metabolic control analysis of anaerobic glycolysis in human hibernating myocardium replaces traditional concepts of flux control. FEBS Lett. 2002; 517: 245–250.
Lopaschuk G, Stanley W. Glucose metabolism in the ischemic heart. Circulation. 1997; 95: 313–315.
Allman K, Wieland D, Muzik O, Degrado T, Wolfe E, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol. 1993; 22: 368–375.
Bengel F, Ueberfuhr P, Ziegler SI, et al. Effect of cardiac sympathetic innervation on metabolism of the human heart determined by positron emission tomography. Circulation. 1999;110:í.201.
Wiggers H, Noreng M, Paulsen PK, et al. Energy stores and metabolites in chronic reversibly and irreversibly dysfunctional myocardium in humans. JAm Coll Cardiol. 2001; 37: 100–108.
Borgers M, Ausma J. Structural aspects of the chronic hibernating myocardium in man. Basic Res Cardiol. 1995; 90: 44–46.
Ausma J, Wijffels M, van Eys G, et al. Dedifferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation. Am J Pathol. 1997; 151: 985–997.
Depré C, Havaux X, Dion R, Vanoverschelde JL. Morphologic alterations of myocardium under conditions of left ventricular assistance. J Thorac Cardiovasc Surg. 1998; 115: 478–479.
Ausma J, Thonae F, Dispersyn GD, et al. Dedifferentiated cardiomyocytes from chronic hibernating myocardium are ischemia-tolerant. Molec Cell Biochem. 1998; 186: 159–168.
Depré C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999; 99: 578–588.
Razeghi PW, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001; 104: 2923–2931.
Elsässer A, Schlepper M, Kleovekorn WP, et al. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation. 1997; 96: 2920–2931.
Elsaesser A, Greiber S, Hein S, et al. Hibernating myocardium: Upregulation of the caspase-3 gene and reduction of bcl-2. Circulation. 1999;110: I. 758.
Brunken RC, Mody FV, Hawkins RA, Nienaber C, Phelps ME, Schelbert HR. Positron emission tomography detects metabolic viability in myocardium with persistent 24-hour single-photon emission computed tomography 201T1 defects. Circulation. 1992; 86: 1357 1369.
Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98:Ií51-I156.
Schwarz E, Schoendube F, Kostin S, et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol. 1998; 31: 1018–1026.
Nienaber CA, Brunken RC, Sherman CT, et al. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty [see comments]. J Am Coll Cardiol. 1991; 18: 966–978.
Vanoverschelde JL, Depre C, Gerber BL, et al. Time course of functional recovery after coronary artery bypass graft surgery in patients with chronic left ventricular ischemic dysfunction. Am J Cardiol. 2000; 85: 1432–1439.
Marwick T, MacIntyre W, Lafont A, Nemec J, Salcedo E. Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function, and metabolism. Circulation. 1992; 85: 1347–1353.
Stevenson W, Stevenson L, Middlekauff H, et al. Improving survival for patients with advanced heart failure: A study of 737 consecutive patients. J Am Coll Cardiol. 1995; 26: 1417–1423.
Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983; 68: 785–795.
Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with low ejection fraction. N Engl J Med. 1985; 312: 1665–1671.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. JAm Coll Cardiol. 2002; 39: 1151–1158.
Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease [see comments]. JAm Coll Cardiol. 1997; 30: 1693–1700.
Landoni C, Lucignani G, Paolini G, et al. Assessment of CABG-related risk in patients with CAD and LVD. Contribution of PET with [18F] FDG to the assessment of myocardial viability. J Cardiovasc Surg. 1999; 40: 363–372.
Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol. 1989; 64: 860–865.
Tamaki N, Yonekura Y, Yamashita K, et al. Prediction of reversible ischemia after coronary artery bypass grafting by positron emission tomography. J Cardiol. 1991; 21: 193201.
Carrel T, Jenni R, Haubold-Reuter S, Von Schulthess G, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg. 1992; 6: 479–484.
Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med. 1992; 19: 874–881.
Marwick TH, Maclntyre WJ, Lafont A, Nemec JJ, Salcedo EE. Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism. Circulation. 1992; 85: 1347–1353.
Gropler RJ, Geltman EM, Sampathkumaran K, et al. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol. 1993; 22: 1587–1597.
Baer FM, Voth E, Deutsch HJ, et al. Predictive value of low dose dobutamine trans-esophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol. 1996; 28: 60–69.
Marwick TH, Nemec JJ, Lafont A, Salcedo EE, Maclntyre WJ. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol. 1992; 69: 854–859.
Paolini G, Lucignani G, Zuccari M, et al. Identification and revascularization of hibernating myocardium in angina-free patients with left ventricular dysfunction. Eur J Cardio-Thorac Surg. 1994; 8: 139–144.
vom Dahl J, Eitzman D, Al-Aouar A, et al. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. Circulation. 1994; 90: 2356–2366.
Bax JJ, Valkema R, Visser FC, et al. Detection of myocardial viability with F-18-fluorodeoxyglucose and single photon emission computed tomography [editorial]. Giorn Ital Cardiol. 1997; 27: 1181–1186.
Flameng WJ, Shivalkar B, Spiessens B, et al. PET scan predicts recovery of left ventricular function after coronary artery bypass operation. Ann Thorac Surg. 1997; 64: 1694–1701.
Fath-Ordoubadi F, Pagano D, Marinho NV, Keogh BE, Bonser RS, Camici PG. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction. Am J CardioL 1998; 82: 26–31.
Akinboboye 00, Idris O, Cannon PJ, Bergmann SR. Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. Am J Cardiol. 1999; 83: 1271–1274.
Pagano D, Townend JN, Littler WA, Horton R, Camici PG, Bonser RS. Coronary artery bypass surgery as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg. 1998; 115: 791–799.
Marwick T, Nemec J, Lafont A, Salcedo E, Maclntyre W. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol. 1992; 69: 854–859.
Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999; 33: 750–758.
Haas F, Augustin N, Holper K, et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomographic findings. J Am Coll Cardiol. 2000; 36: 1927–1934.
Eitzman D, Al-Aouar Z, Vom Dahl J, Kirsh M, Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with Positron Emission Tomography. J Am Coll Cardiol. 1992; 20: 559–565.
Di Carli M, Davidson M, Little R, et al. Value of metabolic imaging with Positron Emission Tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994; 73: 527–533.
Rohatgi R, Epstein S, Henriquez J, Ababneh AA, Hickey KT, Pinsky D, Akinboboye O, Bergmann SR. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 2001;87: 1096–1099, A6.
Bax JJ, Visser FC, Poldermans D, et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med. 2001; 42: 79–86.
Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995; 92: 3436–3444.
Goldman L, Hashimoto B, Cook E, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981; 64: 1227–1234.
Tamaki N, Kawamoto M, Takahashi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thallium imaging. J Am Coll Cardiol. 1993; 22: 1621–1627.
Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation. 1994; 90: 2687–2694.
Zhang X, Liu XJ, Wu Q, et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (l8)F-FDG PET. J Nucl Med. 2001; 42: 1166–1173.
Gioia G, Powers J, Heo J, Iskandrian AS. Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardi0L 1995; 75: 759–762.
Gioia G, Milan E, Giubbini R, DePace N, Heo J, Iskandrian AS. Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. J Nucl Cardiol. 1996; 3: 150–156.
Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997; 96: 793–800.
Petretta M, Cuocolo A, Bonaduce D, et al. Incremental prognostic value of thallium reinjection after stress-redistribution imaging in patients with previous myocardial infarction and left ventricular dysfunction. J Nucl Med. 1997; 38: 195–200.
Cuocolo A, Petretta M, Nicolai E, et al. Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. Eur J Nucl Med. 1998; 25: 60–68.
Dreyfus GD, Duboc D, Blasco A, et al. Myocardial viability assessment in ischemic cardiomyopathy: benefits of coronary revascularization. Ann Thorac Surg. 1994;57:14021407; discussion 1407–1408.
Brunken R, Schwaiger M, Grover-McKay M, Phelps ME, Tillisch J, Schelbert HR. Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol. 1987; 10: 557–567.
Brunken RC, Kottou S, Nienaber CA, et al. PET detection of viable tissue in myocardial segments with persistent defects at T1–201 SPECT. Radiology. 1989; 172: 65–73.
Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol. 1996; 27: 132–139.
Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol. 1998; 32: 921–926.
Anselmi M, Golia G, Cicoira M, et al. Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients. Am J Cardiol. 1998; 81: 21G - 28G.
Meluzin J, Cerny J, Frelich M, et al. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. Investigators of this Multicenter Study. J Am Coll Cardiol. 1998; 32: 912–920.
Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol. 1999; 33: 1848–1854.
Smart SC, Dionisopoulos PN, Knickelbine TA, Schuchard T, Sagar KB. Dobutamineatropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction. J Am Coll Cardiol. 1999; 33: 512–521.
Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999; 100: 1992 2002.
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000; 343: 1445–1453.
Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JAC. Accuaracy of contrast-enhanced magnetic resonance imaging in predicting improvement in regional myocardial function in patients after acute myocardial infarction. Circulation. 2002; 101: 1083–1089.
Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002; 105: 162–167.
Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18Ffluorodeoxyglucose. Circulation. 1991; 83: 26–37.
Box JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici G. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med Mol Imaging. 2002; 29: 721–727.
Schwaiger M, Brunken RC, Krivokapich J, et al. Beneficial effect of residual anterograde flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J. 1987; 8: 981–988.
Czernin J, Porenta G, Brunken R, et al. Regional blood flow, oxidative metabolism, and glucose utilization in patients with recent myocardial infarction. Circulation. 1993; 88: 884–895.
Feigl E, Neat G, Huang A. Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow. J Mol Cell Cardiol. 1990; 22: 375–390.
Maes A, Van de Werf F, Nuyts J, Bormans G, Desmet W, Mortelmans L. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. Circulation. 1995; 92: 2072–2078.
Louie HW, Laks H, Milgalter E, et al. Ischemic cardiomyopathy. Criteria for coronary revascularization and cardiac transplantation. Circulation. 1991;84:I1I290–III295.
Duong T, Hendi P, Fonarow G, et al. Role of Positron Emission Tomographic assessment of myocardial viability in the management of patients who are referred for cardiac transplantation. Circulation. 1995; 92: I - 123.
Duong T, Fonarow G, Laks H, et al. Cost effectiveness of Positron Emission Tomography (PET) in the management of ischemic cardiomyopathy patients who are referred for cardiac transplantation. J Am Coll Cardiol. 1996; 27: 144A.
Maes AF, Van de Werf F, Mesotten LV, et al. Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate. J Am Coll Cardiol. 2001; 37: 30–36.
Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker LC. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation. 1996; 93: 915–923.
Becker DM, Yook RM, Moy TF, Blumenthal RS, Becker LC. Markedly high prevalence of coronary risk factors in apparently healthy African-American and white siblings of persons with premature coronary heart disease. Am J Cardiol. 1998; 82: 1046–1051.
Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation. 1994; 89: 1530–1538.
Furuyama H, Odagawa Y, Katoh C, et al. Assessment of coronary function in children with a history of Kawasaki disease using (15)0-water positron emission tomography. Circulation. 2002; 105: 2878–2884.
Hernandez-Pampaloni M, Allada V, Fishbein MC, Schelbert HR. Myocardial perfusion and viability by PET in infants and children with coronary abnormalities: correlation with echocardiography, cor angiogr histopathol. J Am Coll Cardiol. 2002; 41: 618–626.
Bengel FM, Ueberfuhr P, Nekolla S, Ziegler SI, Reichart B, Schwaiger M. Oxidative metabolism of the transplanted human heart assessed by positron emission tomography using C-11 acetate. Am J Cardiol. 1999;83: 1503–1505, A8.
Bengel FM, Ueberfuhr P, Ziegler SI, Nekolla S, Reichart B, Schwaiger M. Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. A longitudinal study using PET and C-11 hydroxyephedrine. Circulation. 1999; 99: 1866–1871.
Annane D, Duboc D, Mazoyer B, et al. Correlation between decreased myocardial glucose phosphorylation and the DNA mutation size in myotonic dystrophy. Circulation. 1994; 90: 2629–2634.
Annane D, Merlet P, Radvanyi H, et al. Blunted coronary reserve in myotonic dystrophy. An early and gene-related phenomenon. Circulation. 1996; 94: 973–977.
Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001; 357: 279–280.
Di Carli MF, Maddahi J, Rokhsar S, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998; 116: 997 1004.
Rights and permissions
Copyright information
© 2004 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Schelbert, H.R. (2004). Positron Emission Tomography of the Heart: Methodology, Findings in the Normal and the Diseased Heart, and Clinical Applications. In: PET. Springer, New York, NY. https://doi.org/10.1007/978-0-387-22529-6_6
Download citation
DOI: https://doi.org/10.1007/978-0-387-22529-6_6
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-2332-5
Online ISBN: 978-0-387-22529-6
eBook Packages: Springer Book Archive